Reeling From FDA Rejection, Intercept Pharma Slashes Headcount by 25%

Intercept Pharmaceuticals is cutting one-fourth of its workforce, a decision that comes two months after the FDA rejected its drug candidate for the liver disease nonalcoholic steatohepatitis (NASH).